FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079789504> ?p ?o ?g. }

• W2079789504 endingPage "44" @default.
• W2079789504 startingPage "37" @default.
• W2079789504 abstract "Bromocriptine (BC), an ergot alkaloid with wide therapeutic use in humans, has been shown to inhibit proliferation of several abnormally hyperproliferative cells in vivo and in vitro. In the present study, direct effects of BC on mitogen-stimulated proliferation of rat vascular smooth muscle cells (VSMC) (A7r5 cells) and human aortic smooth muscle cells (HAOSMC) were examined in vitro. Twenty-four hour proliferative responses of quiescent A7r5 cells and HAOSMC to a variety of mitogens in the presence or absence of BC were determined by quantifying the incorporation of 3H-thymidine into DNA. BC at 1 μM inhibited the responses of A7r5 cells to various concentrations of fetal calf serum (FCS) by 50–70% without affecting the ED50 of FCS (2%). BC dose dependently inhibited the proliferation of A7r5 cells and HAOSMC stimulated by 2% FCS, with 52% inhibition at 1 and 0.1 μM, respectively. BC at 1 μM also completely inhibited the maximal mitogenic responses of A7r5 cells to prolactin, platelet-derived growth factor, insulin-like growth factor, and phorbol mysterate acetate (PMA), and BC at 1 μM completely inhibited the mitogenic response of HAOSMC to PMA. BC is a dopamine D2 agonist, a noradrenergic α2 agonist, and an α1 antagonist, but the inhibitory effects of BC on A7r5 cell proliferation could not be mimicked by the specific D2 agonists, LY162502 and LY171555; the α2 agonist, clonidine; or the α1 antagonist, WB-4101. Neither dopamine nor the D2 agonist, LY162502, could inhibit HAOSMC proliferation induced by FCS. The PMA-induced stimulation of protein kinase C (PKC), a positive regulator of mitogenesis, could be completely blocked in A7r5 cells and HAOSMC by 1 and 0.1 μM BC, respectively. However, FPCS (2%)-induced activation of PKC in A7r5 cells and HAOSMC could only be blocked by 61 and 19% by BC (1 μM for A7r5 cells and 0.1 μM for HAOSMC), respectively. Given the existing evidence that BC reduces the severity of several other pathological conditions, such as insulin resistance, inflammation, and hyperlipidemia, which potentiate vascular disease, the current findings further suggest that BC use in the treatment of atherosclerosis and/or restenosis deserves further investigation." @default.
• W2079789504 created "2016-06-24" @default.
• W2079789504 creator A5069077456 @default.
• W2079789504 creator A5084493896 @default.
• W2079789504 date "1997-08-01" @default.
• W2079789504 modified "2023-10-16" @default.
• W2079789504 title "Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation" @default.
• W2079789504 cites W1968162244 @default.
• W2079789504 cites W1973543540 @default.
• W2079789504 cites W1975499537 @default.
• W2079789504 cites W1980265413 @default.
• W2079789504 cites W1983985175 @default.
• W2079789504 cites W1990938161 @default.
• W2079789504 cites W2001692359 @default.
• W2079789504 cites W2013430170 @default.
• W2079789504 cites W2021464595 @default.
• W2079789504 cites W2024978314 @default.
• W2079789504 cites W2029026802 @default.
• W2079789504 cites W2031566118 @default.
• W2079789504 cites W2038537788 @default.
• W2079789504 cites W2039928997 @default.
• W2079789504 cites W2046028018 @default.
• W2079789504 cites W2057950504 @default.
• W2079789504 cites W2067395909 @default.
• W2079789504 cites W2069863621 @default.
• W2079789504 cites W2079880694 @default.
• W2079789504 cites W2080605448 @default.
• W2079789504 cites W2107062893 @default.
• W2079789504 cites W2172140351 @default.
• W2079789504 cites W2213615874 @default.
• W2079789504 cites W2402153245 @default.
• W2079789504 cites W4242691368 @default.
• W2079789504 doi "https://doi.org/10.1016/s0021-9150(97)00113-5" @default.
• W2079789504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9258405" @default.
• W2079789504 hasPublicationYear "1997" @default.
• W2079789504 type Work @default.
• W2079789504 sameAs 2079789504 @default.
• W2079789504 citedByCount "16" @default.
• W2079789504 countsByYear W20797895042012 @default.
• W2079789504 countsByYear W20797895042013 @default.
• W2079789504 countsByYear W20797895042014 @default.
• W2079789504 countsByYear W20797895042016 @default.
• W2079789504 countsByYear W20797895042023 @default.
• W2079789504 crossrefType "journal-article" @default.
• W2079789504 hasAuthorship W2079789504A5069077456 @default.
• W2079789504 hasAuthorship W2079789504A5084493896 @default.
• W2079789504 hasConcept C126322002 @default.
• W2079789504 hasConcept C134018914 @default.
• W2079789504 hasConcept C170493617 @default.
• W2079789504 hasConcept C185592680 @default.
• W2079789504 hasConcept C202751555 @default.
• W2079789504 hasConcept C2775960820 @default.
• W2079789504 hasConcept C2776856834 @default.
• W2079789504 hasConcept C2778938600 @default.
• W2079789504 hasConcept C2779064019 @default.
• W2079789504 hasConcept C2779395532 @default.
• W2079789504 hasConcept C2992686903 @default.
• W2079789504 hasConcept C55493867 @default.
• W2079789504 hasConcept C62112901 @default.
• W2079789504 hasConcept C64241487 @default.
• W2079789504 hasConcept C71315377 @default.
• W2079789504 hasConcept C71924100 @default.
• W2079789504 hasConcept C86803240 @default.
• W2079789504 hasConceptScore W2079789504C126322002 @default.
• W2079789504 hasConceptScore W2079789504C134018914 @default.
• W2079789504 hasConceptScore W2079789504C170493617 @default.
• W2079789504 hasConceptScore W2079789504C185592680 @default.
• W2079789504 hasConceptScore W2079789504C202751555 @default.
• W2079789504 hasConceptScore W2079789504C2775960820 @default.
• W2079789504 hasConceptScore W2079789504C2776856834 @default.
• W2079789504 hasConceptScore W2079789504C2778938600 @default.
• W2079789504 hasConceptScore W2079789504C2779064019 @default.
• W2079789504 hasConceptScore W2079789504C2779395532 @default.
• W2079789504 hasConceptScore W2079789504C2992686903 @default.
• W2079789504 hasConceptScore W2079789504C55493867 @default.
• W2079789504 hasConceptScore W2079789504C62112901 @default.
• W2079789504 hasConceptScore W2079789504C64241487 @default.
• W2079789504 hasConceptScore W2079789504C71315377 @default.
• W2079789504 hasConceptScore W2079789504C71924100 @default.
• W2079789504 hasConceptScore W2079789504C86803240 @default.
• W2079789504 hasIssue "1" @default.
• W2079789504 hasLocation W20797895041 @default.
• W2079789504 hasLocation W20797895042 @default.
• W2079789504 hasOpenAccess W2079789504 @default.
• W2079789504 hasPrimaryLocation W20797895041 @default.
• W2079789504 hasRelatedWork W1597151753 @default.
• W2079789504 hasRelatedWork W1969281558 @default.
• W2079789504 hasRelatedWork W1995707202 @default.
• W2079789504 hasRelatedWork W2001778177 @default.
• W2079789504 hasRelatedWork W2010873680 @default.
• W2079789504 hasRelatedWork W2025701518 @default.
• W2079789504 hasRelatedWork W2035004278 @default.
• W2079789504 hasRelatedWork W2043597637 @default.
• W2079789504 hasRelatedWork W2058205365 @default.
• W2079789504 hasRelatedWork W2079101059 @default.
• W2079789504 hasVolume "133" @default.
• W2079789504 isParatext "false" @default.
• W2079789504 isRetracted "false" @default.

• next